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Proper activation of macrophages (Mf) in the inflammatory phase of acute wound healing is essential for
physiological tissue repair. However, there is a strong indication that robust Mf inflammatory responses may be
causal for the fibrotic response always accompanying adult wound healing. Using a complementary approach of
in vitro and in vivo studies, we here addressed the question of whether mesenchymal stem cells (MSCs)—due to
their anti-inflammatory properties—would control Mf activation and tissue fibrosis in a murine model of full-
thickness skin wounds. We have shown that the tumor necrosis factor-a (TNF-a)-stimulated protein 6 (TSG-6)
released from MSCs in co-culture with activated Mf or following injection into wound margins suppressed the
release of TNF-a from activated Mf and concomitantly induced a switch from a high to an anti-fibrotic low
transforming growth factor-b1 (TGF-b1)/TGF-b3 ratio. This study provides insight into what we believe to be a
previously undescribed multifaceted role of MSC-released TSG-6 in wound healing. MSC-released TSG-6 was
identified to improve wound healing by limiting Mf activation, inflammation, and fibrosis. TSG-6 and MSC-based
therapies may thus qualify as promising strategies to enhance tissue repair and to prevent excessive tissue fibrosis.
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INTRODUCTION
Scar formation with persistent alteration of the normal struc-
ture and function of organs following injury is the unavoidable
outcome of adult wound healing in mammals. Excessive
deposition of non-functional extracellular matrix replacing
organ parenchyma may have deleterious consequences.
As skin, as opposed to internal organs, is accessible, it
represents an excellent model to study tissue fibrosis and scar
formation in adult wound healing. Skin scars range from
barely visible fine white lines to disfiguring hypertrophic scars
and keloids causing physical morbidity (Occleston et al.,
2011; Sarrazy et al., 2011). Independent of scar size,
psychological suffering always occurs, and both patients
and physicians would welcome even small improvements in
scar appearance (Young and Hutchison, 2009; Occleston
et al., 2011).
Lessons from scarless fetal wound healing have distinctly
advanced our understanding on underlying mechanisms dif-
ferent from adult healing with scar formation (Longaker et al.,
1994; McCallion and Ferguson, 1997; Cowin et al., 1998).
Key features of inflammation, myofibroblast-driven wound
contraction, and excessive collagen deposition are low or
even absent in fetal scarless healing. By contrast, adult tissue
repair follows a sequence of events with three interdependent
phases, including (1) inflammation, (2) myofibroblast-driven
wound contraction with granulation tissue formation, and (3)
collagen deposition and remodeling (Martin, 1997; Gurtner
et al., 2008). A model has emerged suggesting that scarring
can be caused by dysregulation of any of these phases.
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Within few hours after injury, first polymorphonuclear
neutrophils and later macrophages (Mf) invade the
wound tissue to combat infection and remove tissue debris
by producing reactive oxygen species and proteases. The
inflammatory phase with Mf activation is sustained
by the release of tumor necrosis factor-a (TNF-a), which
exerts autocrine Mf activation (Wang et al., 2006; Sindrilaru
et al., 2011). Upon phagocytosis of polymorphonuclear
neutrophils, Mf release transforming growth factor-b1
(TGF-b1) at the wound site to terminate inflammation and
initiate myofibroblast differentiation with specific expression
of a-smooth muscle actin (a-SMA), the actin isoform which
confers a high contractility of myofibroblasts (Fadok et al.,
1998; Hinz et al., 2001; Peters et al., 2005). The more
extended the inflammatory phase with polymorphonuclear
neutrophils engulfment by Mf, the more excessive the
TGF-b1 release. This essentially controls scar formation
and tissue fibrosis as TGF-b1 stimulates the synthesis of
fibrillar collagen and inhibits collagen degradation by
enhancing tissue inhibitor of matrix metalloproteinase-1
release (Page-McCaw et al., 2007). Despite relevant
progress with prophylactic application of anti-scarring TGF-
b3, occlusive dressings inducing anti-inflammatory inter-
leukin-10 (IL-10), or peptides interfering with myofibroblast
contraction (Occleston et al., 2008), there is still a so far
unmet clinical need to develop more effective anti-scarring
strategies.
Currently, there is an increasing interest in exploiting the
beneficial anti-inflammatory and trophic effects of mesench-
ymal stem cells (MSCs) on homeostasis, repair, and regenera-
tion (Prockop and Olson, 2007). First clinical trials with MSCs
were conducted in osteogenesis imperfecta (Horwitz et al.,
1999), graft-versus-host disease (Le Blanc and Ringden, 2006),
and in three patients suffering from chronic wounds (Falanga
et al., 2007). In murine full-thickness wounds, intravenous
injection of MSCs accelerated wound closure (Wu et al.,
2007) while scar formation and tissue fibrosis has not been
addressed in sufficient molecular detail.
Stimulated by the findings (1) that intravenous injection of
MSCs improved tissue repair in myocardial infarction in mice
by secretion of anti-inflammatory TNF-a-induced protein 6
(TSG-6) (Lee et al., 2009), that (2) TSG-6 is poorly expressed
in human hypertrophic scars (Tan et al., 2011), and most
notably that (3) TSG-6 gene is localized in a keloid
susceptibility region of chromosome 2 (Nentwich et al.,
2002), we set out to study the effect of MSCs on different
phases of adult tissue repair eventually controlling tissue
fibrosis and scar formation.
Here we found that wound closure was accelerated
and tissue fibrosis was significantly reduced following injec-
tion of human MSCs into murine full-thickness wound
margins. We showed that MSC-released TSG-6 not only
suppressed TNF-a-mediated inflammation but in addition
also switched TGF-b1 and TGF-b3 synthesis from a scar-
promoting high to an anti-fibrogenic low TGF-b1/TGF-b3
ratio which, similar to fetal wound healing, reduced myofi-
broblast differentiation and suppressed excessive collagen
deposition.
RESULTS
MSCs suppress pro-inflammatory M/ activation and accelerate
wound healing
Fully characterized bone marrow (BM)-derived MSCs with
plastic adherence, expression of a defined marker profile, and
tri-lineage differentiation potential (Dominici et al., 2006)
have been used (Supplementary Figure S1 online). To study
the impact of local delivery of MSCs on wound repair, wounds
were inflicted on the shaved back of C57BL/6 mice, and
1106 MSCs or phosphate-buffered saline (PBS) were
injected into wound margins 24 h post wounding. Wound
closure of MSC-injected wounds was accelerated, illustrated
by smaller wound areas measured at days 3, 5, 7, and 10 post
wounding (Figure 1a and b) when compared with PBS-
injected control wounds. Masson Trichrome collagen staining
and Picrosirius Red staining with polarized light revealed
significantly reduced tissue fibrosis in day-15 MSC-treated
wounds as compared with control wounds (Figure 1c). Lysates
from Mf purified from day-2 PBS-injected wounds revealed a
strong TNF-a induction measured by enzyme-linked immu-
nosorbent assay (ELISA). By contrast, Mf from MSC-injected
wounds showed a markedly reduced TNF-a release
(Figure 1d). These data were confirmed by double immunos-
taining for Mf-specific F4/80 and TNF-a. Day-2 control
wounds revealed significantly more TNF-a-producing Mf
compared with MSC-treated wounds, whereas overall wound
Mf numbers did not differ (Figure 1e and f), most likely
indicating that Mf recruitment was not affected by MSCs.
These data suggest that TNF-a, at least when released at high
concentrations during acute wound healing, may delay
wound closure.
MSCs suppress pro-inflammatory M/ activation via TSG-6
in vitro
To further assess the mechanism underlying MSC-dependent
downregulation of pro-inflammatory Mf in acute wounds, we
established a MSCs-Mf-co-culture protocol in vitro (Supple-
mentary Figure S2a online). We applied combined treatment
with lipopolysaccharide/interferon-g (LPS/IFN-g) for Mf acti-
vation, as this closely reflects the danger signals occurring
in the wound microenvironment. LPS/IFN-g-activated Mf
released high concentrations of pro-inflammatory nitric oxide
(NO  ), TNF-a, and IL-12. Co-culture of 1106 activated Mf
with 1105 and 2104 MSCs significantly diminished NO  ,
TNF-a, and IL-12 release (Supplementary Figure S2b online).
Given that TNF-a has a major role in impairing wound
healing with a less favorable fibrogenic outcome, we next
studied the role of the TNF-a-induced anti-inflammatory factor
TSG-6 in wound healing. Interestingly, using quantitative
reverse transcriptase–PCR on MSC co-cultures with LPS/IFN-
g-activated Mf, we detected a 50-fold increase in human-
specific TSG-6 (hTSG-6) mRNA compared with MSCs alone
(Figure 2a). This was even significantly higher than the 20-fold
increase observed for recombinant human TNF-a (rhTNF-a)-
stimulated MSCs. Similar results were obtained for TSG-6
protein levels using western blot and semiquantitative densito-
metric analysis (Figure 2b). In addition, incubation of activated
Mf with 10 and 50 ng ml 1 rhTSG-6 significantly suppressed
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TNF-a release from activated Mf, whereas TSG-6 at a higher
concentration of 100 ng ml1 did not further suppress TNF-a
release (Figure 2c). Notably, co-culture of TSG-6-silenced
MSCs with activated Mf almost completely abrogated the
TNF-a-suppressive effect of MSCs (Figure 2d and
Supplementary Figure S3 online). The alleviation of TNF-a
suppression was not observed in co-culture experiments with
MSCs transfected with scrambled (scr) siRNA (Figure 2d).
These data indicate that TSG-6 exerts its anti-inflammatory
effect by suppressing pro-inflammatory TNF-a release.
MSC-derived TSG-6 suppresses pro-inflammatory TNF-a release
from M/ and thereby accelerates wound healing
To further investigate whether MSC-derived TSG-6 sup-
pressed Mf activation during wound healing in vivo, we
first studied TSG-6-specific mRNA expression in MSC-
injected wounds at different time points post wounding. A
strong increase in TSG-6 mRNA levels normalized to human
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was
found already at 6 h post injection with a further time-
dependent increase for the studied time period of 96 h
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Figure 1. Mesenchymal stem cells (MSCs) accelerate anti-fibrogenic healing with suppression of macrophage-derived tumor necrosis factor (TNF)-a.
(a) Representative wounds injected with phosphate-buffered saline (PBS; Co) or MSCs. (b) Statistical analysis of 20 wounds/group expressed as percentage
of day-0 wound size. Results given as mean±SD (n¼5), *Po0.05, **Po0.01, and ***Po0.001 by Mann–Whitney test. (c) Representative photomicrographs
of Masson Trichrome– and Picrosirius Red–stained sections from day-15 wounds injected with PBS (Co) or MSCs. Bars¼ 200mm. (d) TNF-a-specific
enzyme-linked immunosorbent assay of day-2 wound Mf lysates from PBS (Co) or MSC-injected wounds. (e) Immunostaining for TNF-a and F4/80 in
day-2 PBS (Co) or MSC-injected wounds. Bars¼25mm. (f) Quantification of total and TNF-aþF4/80þ Mf in PBS and MSC-injected wounds. Sections from
eight wounds per group were analyzed in 15 high-power fields (HPF) per section. Results given as mean±SD (n¼4), ***Po0.001 by Student’s t-test. DAPI,
4,6-diamidino-2-phenylindole.
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(Figure 3a). Double staining for human beta-2-microglobulin
(b2M) (green) and hTSG-6 (red) revealed distinct TSG-6-
expressing MSCs (yellow) in day-2 MSC-injected wounds,
but not in PBS-injected wounds, excluding cross-reactivity of
the anti-hTSG-6 and anti-b2M antibodies with the murine
homologs (Figure 3b). Topical delivery of BM-derived
MSCs from acrylic acid–coated silicone-based carriers
also resulted in TSG-6 release in the wound bed
(Supplementary Figure S6 online). To monitor whether
MSC-derived TSG-6 can counterbalance pro-inflammatory
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Figure 2. Mesenchymal stem cell (MSC)-derived TNF-a-induced protein 6 (TSG-6) suppresses macrophage activation in vitro. (a) Reverse transcriptase–PCR
for TSG-6 in non-activated bone marrow (BM)-MSCs, tumor necrosis factor (TNF)-a-treated BM-MSCs, and BM-MSC-activated Mf co-cultures. Results given as
mean TSG-6/GAPDH (glyceraldehyde 3-phosphate dehydrogenase) expression±SD (n¼ 3), *Po0.05, ***Po0.001 by Student’s t-test. (b) Western blot of
TSG-6 expression in lysates from non-activated BM-MSCs, TNF-a-treated BM-MSCs, BM-MSCsþnon-activated Mf co-cultures, and BM-MSCsþ activated Mf
co-cultures. Semiquantitative densitometric analysis of digitized blots given as mean TSG-6/b-actin signal±SD (n¼ 3), *Po0.05 by Student’s t-test. (c) TNF-a
enzyme-linked immunosorbent assay with supernatants from non-activated or activated Mf stimulated with recombinant human TSG-6 (rhTSG-6). Results
presented as mean±SD (n¼ 3), *Po0.05 by Student’s t-test. (d) TNF-a concentrations measured in supernatants from non-activated Mf, activated Mf, co-cultures
of activated Mf with BM-MSCs, TSG-6 small interfering RNA (siRNA)-silenced BM-MSCs, or scrambled (scr) siRNA-transfected BM-MSCs. Data given as
mean±SD (n¼ 3), *Po0.05, **Po0.01 by Student’s t-test.
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activated Mf, rhTSG-6 was injected into wounds at day 2
post wounding. This resulted in an impressive reduction in
TNF-a levels in the lysates of day-3 wounds (Figure 3c).
Immunofluorescent staining of rhTSG-6-injected wounds
confirmed significantly reduced TNF-aþF4/80þ Mf num-
bers compared with control wounds (data not shown).
Moreover, the injection of TSG-6-silenced MSCs abolished
suppression of TNF-a release (Figure 3d).
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Figure 3. Mesenchymal stem cell (MSC)-derived TNF-a-induced protein 6 (TSG-6) reduces tumor necrosis factor (TNF)-a and improves wound closure in vivo.
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These data indicate that MSC-derived TSG-6 suppressed Mf
TNF-a synthesis, thus disrupting the previously reported
autocrine amplification of Mf activation (Wang et al., 2008;
Sindrilaru et al., 2011). This may be particularly important, as
TNF-a released from activated Mf enhances the inflammatory
response, overall tissue breakdown, and most likely scar
formation. Therefore, we next studied whether MSC-derived
TSG-6 contributed to the observed acceleration of wound
healing. Indeed, injection of MSCs into wound margins
significantly accelerated wound healing. Notably, this
beneficial effect was almost completely abrogated with TSG-
6 siRNA-silenced MSCs but preserved with scr siRNA-
transfected MSCs (Figure 3e).
MSC-derived TSG-6 reduces tissue damage and granulation
tissue formation
To substantiate the hypothesis that due to diminished inflam-
mation and tissue damage the granulation tissue formation
with myofibroblasts differentiation is reduced in MSC-injected
wounds, we analyzed granulation tissue formation in differ-
ently treated wounds. We found that a-SMA expression, while
enhanced at day-5 wounds, is significantly reduced at days 7
and 10 in the MSC-injected wounds in a TSG-6-dependent
manner (Figure 4a and b). The decreased expression of a-SMA
on day-10 wounds was also confirmed by immunofluorescent
staining. In this context, reduced cell numbers revealed a faint
a-SMA staining in day-10 wounds injected with MSCs, when
compared with the corresponding areas in the PBS-injected
wounds (Figure 4c). The injection of rhTSG-6 at days 2 and 3
post wounding also showed a significant reduction in a-SMA
expression compared with the PBS-injected in day-10-old
wounds (Supplementary Figure S5 online). These results
indicate that lower numbers of myofibroblasts reside in the
wound bed of both MSCs and rhTSG-6-injected wounds
compared with control wounds, suggesting that TSG-6 is
responsible for the suppressive effect on myofibroblast differ-
entiation, a key feature of granulation tissue formation.
MSC-derived TSG-6 markedly suppresses tissue fibrosis
To further investigate whether reduced myofibroblast differ-
entiation, as observed in acute wounds injected with MSCs or
rhTSG-6, may lead to reduced scar formation, we studied the
effects of MSCs and MSC-derived TSG-6 on tissue fibrosis.
Compared with control wounds, Masson Trichrome staining
for fibrillar collagens revealed a significantly reduced scar
depth and tissue fibrosis in MSC-injected wounds (Figure 5a
and b). This was particularly evident at higher magnification
(Figure 5a and b, right panels). Although day-15 PBS-injected
wounds revealed densely packed and disorganized thick
collagen fibrils in a fibrotic tissue, MSC-injected wounds
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Figure 4. Mesenchymal stem cells (MSCs) reduce granulation tissue formation. (a) Western blot analysis of a-smooth muscle actin (a-SMA) from wound lysates of
day-5, -7, and -10 wounds injected either with phosphate-buffered saline (PBS; Co), MSCs, TNF-a-induced protein 6 (TSG-6)-silenced MSCs, or srambled
(scr) small interfering RNA (siRNA)-transfected MSCs. (b) Semiquantitative densitometric analysis of digitized blots given as mean a-SMA/b-actin signal±SD
(n¼ 5), *Po0.05, ***Po0.001 by Student’s t-test; NS, not significant. (c) Immunostaining for the classical myofibroblast-specific marker a-SMA of wound sections
derived from day-10 wounds injected with PBS (Co) or MSCs 24 h after wounding. Bars¼100mm. DAPI, 4,6-diamidino-2-phenylindole.
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showed reduced thickness of collagen fibrils well organized in
a basket-weave pattern (Figure 5a and b, right panels). TSG-6-
silenced MSC-injected wounds did not markedly show
reduced fibrosis compared with MSC-injected wounds
(Figure 5c). Quantification of fibrotic tissue depth confirmed
a highly significant reduction in fibrotic tissue depth in serial
sections of MSC-injected wounds when compared with PBS-
injected wounds (Figure 5d). The beneficial anti-fibrotic effect
was partly reversed in wounds injected with TSG-6-silenced
MSCs, indicating that TSG-6 has a causal though not exclusive
role in reducing tissue fibrosis by MSCs (Figure 5d).
Depending on the extent of inflammation and myofibroblast
differentiation, procollagen type I and III are produced in the
matrix deposition and remodeling phase of tissue repair. The
extent of collagen deposition represents a valuable indicator
for tissue fibrosis and scar formation (Kokot et al., 2009).
Notably, quantitative reverse transcriptase–PCR for specific
a1(I), a2(I), and a1(III) collagen chains showed a significant
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Figure 5. Mesenchymal stem cell (MSC)-derived TNF-a-induced protein 6 (TSG-6) contributes to reduced tissue fibrosis. Representative photomicrographs of
Masson Trichrome–stained sections from day-15 wounds injected with (a) phosphate-buffered saline (PBS; Co), (b) MSCs, or (c) TSG-6-silenced MSCs. Collagen
fibrils stained blue. Epidermis and hair follicles stained brownish-red. White arrows indicate fibrotic tissue depths. The white rectangles indicate the area of
magnification as shown in the outer right panels. Bars¼ 100mm. (d) The fibrotic tissue depths were quantified in serial sections in the center of day-15 wounds
treated with PBS (Co), MSCs, or TSG-6-silenced MSCs. Assessment of fibrotic tissue depths was done in a blinded fashion. Results presented as mean±SD (n¼5).
***Po0.001 by Student’s t-test. Reverse transcriptase–PCR of (e) cola1(I), (f) cola2(I), and (g) cola1(III) expression levels for day-2, -5, -10, -21, and -42 PBS (Co) or
MSC-injected wounds. Results expressed as mean±SD (n¼ 5), *Po0.05, **Po0.01, ***Po0.001 by Student’s t-test. (h) Following pepsin digestion, equal protein
concentration of lysates for PBS (Co) or MSC-injected wounds were subjected to gel electrophoresis and subsequent Coomassie blue staining. (i) Breaking strength
was measured as the ratio of wounds versus corresponding normal skin from PBS (Co) or MSC-treated mice at days 21and 42 post wounding. Results are expressed
as mean±SD (n¼5), *Po0.05, by Student’s t-test.
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reduction in mRNA levels of all the studied collagens in MSC-
injected day-2, -5, and -10 wounds, when compared with
control wounds (Figure 5e–g). This beneficial effect was, at
least in part, abrogated by TSG-6-silenced MSCs (data not
shown), very much suggesting that collagen mRNA synthesis
is repressed by MSC-released TSG-6. Similar data with
reduced a1 and a2 collagen type I chains were obtained as
assessed by Coomassie blue staining (Figure 5h). Although
mRNA levels of collagen chains did not differ in day-21 and -
42 wounds (Figure 5e–g), overall collagen protein content
remained reduced at all the studied time points (Figure 5h).
These data show that reduced collagen synthesis at early
stages of wound healing result in overall reduced collagen
deposition at later stages of wound healing with overall
reduced tissue fibrosis.
In order to study tensile strength and the functionality of
MSC-injected wounds, the breaking strength of restored tissue
from PBS- and MSC-treated wounds at days 21 and 42 post
wounding was assessed. In fact, MSC-injected wounds sig-
nificantly enhanced the wound-breaking strength compared
with PBS-injected wounds at days 21 and 42 post wounding
(Figure 5i). These data indicate that the functionality of tissue
fibrosis–reduced wounds after MSC injection in terms of
breaking strength is markedly better compared with that of
PBS-injected wounds and is even similar to the breaking
strength of uninjured normal skin. Collectively, these data
show that the quality of tissue fibrosis is significantly improved
by MSC-derived TSG-6.
TSG-6 exerts its anti-fibrotic effect via a reduced TGF-b1/TGF-b3
ratio
MSC-released TSG-6 suppressed myofibroblast differentiation
and tissue fibrosis, which very much depend on TGF-b1
concentrations, while TGF-b3 rather suppressed myofibroblast
differentiation and tissue fibrosis (Shah et al., 1992; Occleston
et al., 2011). We here assessed the hypothesis whether TSG-6,
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in addition to its known inflammation-dampening properties,
may impact on TGF-b1 and TGF-b3 concentrations promoting
a lower TGF-b1/TGF-b3 anti-fibrotic ratio, as earlier reported
in scarless fetal and mucosal wound healing (Chen et al.,
2005; Schrementi et al., 2008). In fact, upon injection of
MSCs, TGF-b1 expression was initially increased at day-2 post
wounding most likely contributing to the early increase in a-
SMA expression. At later time points of MSC-injected wounds,
TGF-b1 expression significantly decreased, whereas TGF-b3
expression increased (Figure 6a). Interestingly, this effect was
abolished by the injection of TSG-6-silenced MSCs
(Figure 6b). Notably, injection of rhTSG-6 into acute wounds
significantly decreased active TGF-b1, whereas TGF-b3
concentrations increased as compared with PBS-injected
wounds (Figure 6c). Both MSCs and rhTSG-6 induced a lower,
anti-fibrotic TGF-b1/TGF-b3 ratio as compared with PBS-
injected wounds (Figure 6b and c).
DISCUSSION
This report defines what we believe to be a previously
undescribed property of human MSCs that, when injected
into wound margins, via the release of TSG-6 mediated a so
far unknown switch from a high fibrosis-promoting to a low
anti-fibrotic TGF-b1/TGF-b3 ratio. In addition, MSC-derived
TSG-6 suppressed TNF-a release from pro-inflammatory Mf at
wound sites. The combined TNF-a suppression and the switch
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to a favorable TGF-b1/TGF-b3 ratio eventually resulted in
accelerated wound healing and significantly reduced tissue
fibrosis in murine full-thickness wounds.
Despite distinct differences between murine and human
wound healing (Wong et al., 2011), similar to human wound
healing by secondary intention, murine full-thickness wounds
including the circumscribed excision of the panniculus
carnosus heal via myofibroblast-driven contraction, granu-
lation tissue formation, subsequent collagen deposition, and
scar formation (Peters et al., 2005; Sindrilaru et al., 2009).
Here we provide evidence that all phases of cutaneous
wound healing, including inflammation, granulation tissue
formation, and myofibroblast-dependent tissue fibrosis, are
affected by MSCs and that MSC-released TSG-6 qualifies as an
anti-inflammatory and anti-fibrogenic key molecule in fibrosis-
reduced accelerated adult tissue repair. In fact, TSG-6-
silenced MSCs failed to suppress Mf-derived TNF-a release
in co-cultures with activated Mf and when injected into
wound margins. By contrast, scr siRNA-transfected MSCs
maintained the TNF-a-suppressive effect. Enhanced release
of TNF-a from Mf reflects an evolutionarily shaped response
to injury in pathogen-rich environments that, in its ancient
amplitude, is not fully required in the nowadays pathogen-
reduced environment. Therefore, high concentrations of
TNF-a occurring during adult healing may, via enhanced
M1 Mf activation, rather contribute to enhanced tissue
damage and even promote unfavorable tissue fibrosis and
scar formation in adult wound healing. Consistently, condi-
tional depletion of Mf in the inflammatory phase of wound
healing markedly reduced scar formation in acute wounds
(Lucas et al., 2010). In chronic wounds with unrestrained
inflammation and TNF-a concentrations exceeding those of
acute wounds, the TNF-a antagonist etanercept fully restored
physiological TNF-a concentrations and improved wound
healing (Sindrilaru et al., 2011). In addition, MSC-derived
TSG-6 has been reported to enhance tissue repair in
experimental myocardial infarction (Lee et al., 2009). Our
data corroborate and extend previous findings that human
gingival or BM-derived MSCs suppress TNF-a release from Mf
in vitro and in vivo (Maggini et al., 2010; Zhang et al., 2010).
The present approach highlights the usefulness of a more
complete assessment of MSCs injected into wound margins
and helped to identify the so far unknown function of TSG-6
to tilt TGF-b1 and TGF-b3 concentrations to an anti-fibro-
genic ratio. Several lines of experimental evidence support
this notion. First, either rhTSG-6 or, alternatively, TSG-6-
releasing MSCs suppressed TGF-b1 concentrations and sub-
stantially increased the anti-fibrogenic TGF-b3 in wound
margins. Second, TGF-b1 preferentially released by Mf
(Werner and Grose, 2003) at the late inflammatory phase
initiates granulation tissue formation by driving myofibroblast
differentiation and collagen deposition. In this aspect, TGF-b1
supports excessive and unorganized collagen deposition as
seen in scars and fibrotic disorders (Ignotz and Massague,
1986). By contrast, TGF-b3 exerts opposing effects by
suppressing myofibroblast differentiation and collagen
synthesis and promoting a scar texture and functional
quality reminiscent of normal skin. Notably, injection of
rhTSG-6 or MSCs, via a TSG-6-dependent switch to a low
TGF-b1/TGF-b3 ratio, significantly reduced myofibroblast
differentiation, collagen type I deposition, tissue fibrosis,
and distinctly improved the scar quality as shown by
improved breaking strength.
Thus, our findings describe a wound-healing mechanism
very much resembling fetal wound healing, which consistently
lacks inflammation with only low pro-inflammatory Mf
numbers, reduced pro-inflammatory cytokines (Liechty et al.,
2000), low myofibroblasts numbers, and low TGF-b1/TGF-b3
ratio compared with fibrogenic adult wound healing (Mast
et al., 1992; Hopkinson-Woolley et al., 1994; Armstrong
and Ferguson, 1995). In fact, fetal wound healing relies
on regenerative progenitor cells and their appropriate
microenvironmental niche. Interestingly, disruption of this
niche by TGF-b1 injection leads to scar formation in fetal
wounds (Lin et al., 1995). Though not proven, MSCs most
likely interpret microenvironmental cues and execute
decisions to maintain their niche homeostasis. In this report,
we have shown MSCs, even if injected into wound margins, to
maintain this capacity to revert the pro-inflammatory and
fibrogenic to an anti-inflammatory and anti-fibrogenic
environment. In the hostile inflammatory wound environ-
ment with high TNF-a concentrations, MSCs upregulated
anti-inflammatory TSG-6 and anti-fibrotic TGF-b3, thereby
distinctly rerouting adult wound healing towards accelerated
fibrosis-reduced tissue repair.
Our data sustain the notion that an early increase of a-
SMAþ myofibroblasts with enhanced myofibroblast-depen-
dent wound contraction is most likely due to an early TGF-b1
peak in lysates from day-2 wounds injected with MSCs. In
fact, injection of TGF-b1-silenced MSCs, at least in part,
abrogates this effect (data not shown). In addition, the TSG-
6-dependent reduction of the TNF-a release from M1 Mf
results in reduced tissue damage and an overall reduced
wound size. Importantly, the effects of the TSG-6-dependent
switch to a low anti-fibrogenic TGF-b1/TGF-b3 ratio kick in
later and are responsible for reduced a-SMAþ myofibroblast
numbers in day-7 and -10 wounds as well as for reduced
tissue fibrosis.
Excessive TGF-b1 has long been detected to drive the
pathogenesis of hypertrophic scars and keloids (Lee et al.,
1999). Much effort has been focused to uncover function-
relevant polymorphisms in the TGF-b1 gene, with no success
so far. Our finding that TSG-6 tilts the TGF-b1/TGF-b3
concentrations to an anti-fibrogenic ratio may shed light on
the pathogenesis of fibrosis and scar formation. In fact,
polymorphisms in the TSG-6 gene confer susceptibility to
hypertrophic scar and keloid formation, and TSG-6 expression
is markedly reduced in hypertrophic scar and keloids (Tan
et al., 2011).
The TSG-6-dependent switch from the fibrogenic high to an
anti-fibrogenic low TGF-b1/TGF-b3 ratio was found by a
cross-species strategy of injecting human MSCs into C57BL/
6J mice. We have purposely used this strategy, as we wished
to focus our studies on the paracrine effects of ‘‘tissue-
restoring’’ factors in acute full-thickness wounds. In addition,
human MSCs, in part due to absent MHCII expression, are
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immunoprivileged, and human-specific Alu DNA
sequences were detectable for at least 3 days at murine
wound sites (Supplementary Figure S4 online), suggesting that
xenotransplanted MSCs neither engrafted nor differentiated
into histogenetically distinct skin cells. We are confident that
our cross-species approach is not flawed by artifacts, as
rhTSG-6 injection could reproduce the anti-inflammatory
and anti-fibrogenic effects of MSCs. Similar experimental
approaches with human MSCs in animal models have
successfully been used, and obvious cross-species artifacts
have not been reported (Bai et al., 2009; Lee et al., 2009;
Choi et al., 2011).
Apart from TSG-6, it is likely that other anti-inflammatory
and anti-fibrotic molecules released by MSCs further
contribute. A variety of anti-inflammatory factors, like IL-10
(Supplementary Figure S2c online), IL-4, hepatocyte growth
factor, prostaglandin E2, and stanniocalcin-1 may have an
additional role (Prockop and Oh, 2012).
Taken together, our findings provide powerful insight into a
facet of TSG-6 released from MSCs in acute wound healing
and its anti-fibrogenic properties of enhanced tissue repair.
Both MSCs and the MSC-derived TSG-6 hold substantial
promise for the development of anti-fibrotic therapies.
Though our prime interest was to study mechanisms under-
lying reduced tissue fibrosis in physiological adult wound
healing following injection of either MSCs or rhTSG-6, it will
be of major importance to also characterize the effect of
MSCs/TSG-6 on wound models with enhanced mechanical
load-dependent excessive scarring (Aarabi et al., 2007; Wong
et al., 2011) in future studies.
MATERIALS AND METHODS
Cell isolation and culture
Human BM-derived MSCs were obtained from the human hip BM,
regularly assessed for the required expression of cell surface markers
and their differentiation capacity into adipogenic, chondrogenic, and
osteogenic lineages (Supplementary Figure S1 online; Dominici et al.,
2006), and cultured as described (Fekete et al., 2012). MSCs from
passages 1–4 were used in the experiments.
Mouse BM-derived Mf were isolated from femurs as described
(Peters et al., 2005). Five-day-old Mf were activated with 20 ng ml 1
LPS and 50 U ml 1 recombinant mouse IFN-g and further used for
in vitro experiments (R&D, Wiesbaden, Germany).
For wound Mf isolation, mouse wounds were minced and digested
with 1.5 mg collagenase and hyaluronidase (Sigma-Aldrich, Tauf-
kirchen, Germany) for 1 h at 37 1C. Cell suspensions were incubated
with biotinylated anti-mouse F4/80 antibody (eBioscience, Frankfurt,
Germany) followed by anti-biotin MicroBeads and passed through an
LS column (Miltenyi Biotec, Bergisch Gladbach, Germany) in a
magnetic field. Protein lysates from MACS-purified Mf were subjected
to ELISA or sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Co-culture experiments
MSCs were plated to adhere at 1 105, 2 104, or 5000 cells/well in
six-well plates (Thermo Scientific, Langenselbold, Germany); after
24 h Mf were seeded on top of MSCs at 1 106 cells/well. MSCs-
Mf-co-cultures were stimulated with 20 ng ml 1 LPS and 50 U ml 1
IFN-g for 48 h before further analysis.
TSG-6 siRNA transfection
MSCs were transfected with either 20 nM TSG-6 siRNA (Santa Cruz,
Heidelberg, Germany) or scrambled (scr) siRNA-A, scr siRNA-B, scr
siRNA-C (all from Santa Cruz), or scr siRNA (Qiagen, Hilden,
Germany) diluted in transfection medium. TSG-6-silenced MSCs
and MSCs transfected with different scr siRNAs were co-incubated
for another 48 h with the TSG-6 inducer rhTNF-a as positive control
(R&D), with resting Mf or activated Mf. Suppression efficiency was
assessed by TSG-6 protein expression by ELISA and was 98%.
Mice and wound-healing model
All experiments were performed with 8–12 weeks C57BL/6 mice
(University of Ulm animal facility) in compliance with the German
Law for Welfare of Laboratory Animals and were approved by the
Institutional Review Board of the University of Ulm.
Four 6-mm full-thickness excisional wounds were made under
anesthesia on the backs of every mouse as described (Peters et al.,
2005). In all, 10mg per wound rhTSG-6 (R&D) was injected intrader-
mally around wound margins at days 2 and 3 post wounding, PBS
served as control; in other experiments 1 106 MSCs, scr siRNA or
TSG-6 siRNA-transfected MSCs per mouse were injected around
wound margins 24 h post wounding. At the indicated time points,
wounds were photographed and quantified as described (Sindrilaru
et al., 2009) using Adobe Photoshop 7.0.1 software (Adobe Systems,
San Jose, CA). Photography and wound area analyses were done in a
blinded fashion in that the investigators were unaware of which were
treated wounds and which were not.
Statistical analysis
Quantitative data are presented as mean values±SD. Unless other-
wise stated, two-tailed unpaired Student’s t-tests were used to
determine statistical significance.
Additionally used techniques are available in the Supplementary
Information online.
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